Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing-Patient's Willingness-to-Pay: A Brief Report.
Chen KH, Barnes TA, Laskin J, Cheema P, Liu G, Iqbal M, Rothenstein J, Burkes R, Tsao MS, Leighl NB. Chen KH, et al. Among authors: leighl nb. JTO Clin Res Rep. 2023 Nov 28;5(1):100615. doi: 10.1016/j.jtocrr.2023.100615. eCollection 2024 Jan. JTO Clin Res Rep. 2023. PMID: 38292413 Free PMC article.
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP, David Walde PL, Rudinskas LC, Rahim YH, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Clin Lung Cancer. 2003 Sep;5(2):107-12. doi: 10.3816/CLC.2003.n.024. Clin Lung Cancer. 2003. PMID: 14596693 Clinical Trial.
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Lung Cancer. 2006 Jun;52(3):327-32. doi: 10.1016/j.lungcan.2006.02.006. Epub 2006 Apr 4. Lung Cancer. 2006. PMID: 16597474 Clinical Trial.
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A, Ludkovski O, Ma C, Squire J, Liu G, Shepherd FA, Tsao MS, Leighl NB. Lara-Guerra H, et al. Among authors: leighl nb. J Clin Oncol. 2009 Dec 20;27(36):6229-36. doi: 10.1200/JCO.2009.22.3370. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884551 Clinical Trial.
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB; NCIC Clinical Trials Group Working Group on Economic Analysis. Bradbury PA, et al. Among authors: leighl nb. J Natl Cancer Inst. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16. J Natl Cancer Inst. 2010. PMID: 20160168
300 results